| Literature DB >> 32573374 |
Shasank S Swain1, Divakar Sharma2, Tahziba Hussain1, Sanghamitra Pati3.
Abstract
Nowadays, drug-resistant tuberculosis (DR-Entities:
Keywords: Multi-drug-resistant tuberculosis; anti-tubercular natural products; drug resistance mechanisms; genetic factors; mutations
Mesh:
Substances:
Year: 2020 PMID: 32573374 PMCID: PMC7473167 DOI: 10.1080/22221751.2020.1785334
Source DB: PubMed Journal: Emerg Microbes Infect ISSN: 2222-1751 Impact factor: 7.163
Figure 1.Successful anti-TB drugs from natural sources.
Figure 2.A schematic representation of the drug-resistant mechanism of mycobacterium tuberculosis.
Figure 3.A schematic representation of genetic mutations associated with the drug-resistant mechanism of rifampicin targeting rpoB.
Figure 4.Newly identified anti-TB drug development targets and pipeline drugs.
Genetic factors involved in first-line anti-TB drug resistance in Mycobacterium tuberculosis.
| Drug (year) | Chemical class (activity type) | Inhibition target (associated action) | MIC (mg/L) | Genetic factor | Associated function | Drug resistance | Reference |
|---|---|---|---|---|---|---|---|
| Isoniazid (1952) | Isonicotinic acid (bactericidal) | Enoyl-(acyl-carrier-protein) reductase including, catalase peroxidase, NADH-dependent enoyl ACP, 3-Oxoacy ACP, | 0.02-0.2 | katG | Intracellular survival | Modification overexpression of drug target due to mutations and altered efflux pump activity and pro-drug conversion | [ |
| inhA | Mycolic acid biosynthesis | ||||||
| kasA | Fatty acid biosynthesis | ||||||
| AhpC | Defence from oxidative stress | ||||||
| niA | Associated with efflux pump | ||||||
| FadE24 | Degradation lipid and fatty acid | ||||||
| ndh | Electron transference from NADH to the respiratory chain | ||||||
| FabG1 | Fatty acid biosynthesis pathway | ||||||
| Rifampicin (1963) | Rifamycin (bactericidal) | RNA polymerase, | 0.05-1.0 | rpoB | Catalyze the transcription for DNA into RNA synthesis | Modification in drug target due to mutations | [ |
| Ethambutol (1961) | Ethylenediamine (bacteriostatic) | Arabinosyl transferase (inhibition of arabinogalactan synthesis) | 1–5 | emb A, B and C | Associated with biosynthesis of the mycobacterial cell wall | Change and overexpression of drug target; and altered efflux pump activity | [ |
| embR | embCAB operon synthesis regulator | ||||||
| rmLD | dTDP-L-rhamnose biosynthesis | ||||||
| iniA | Associated with efflux pump | ||||||
| Pyrazinamide (1952) | Pyrazine (bacteriostatic/bactericidal) | Pyrazinamidase; ribosomal protein 1 30S ribosomal subunit, cytoplasm | 16–100 | pncA | To converts amides into acid | Abolition of pro-drug conversion mechanism | [ |
| rpsA | Translate mRNA with a shine-dalgarno purine-rich sequence | ||||||
| panD | Pantothenate biosynthesis | ||||||
| clpC1 | Protein degradation, hydrolyses proteins in the presence of ATP | ||||||
| gpsI | Involved in mRNA degradation | ||||||
| Streptomycin (1944)* | Aminoglycoside (bacteriostatic) | 30S, 16S ribosomal protein and 7-methyl guanosine methyl-transferase (inhibition of arabinoga-lactan and protein synthesis) | 2–8 | rpsL | Translation initiation step | Variation in drug target binding site due to mutations | [ |
| rrs | Synthesis of stable RNAs | ||||||
| gidB | Probable glucose-inhibited division protein B |
*, injectable.
Genetic factors involved in second-line anti-TB drug resistance in Mycobacterium tuberculosis.
| Drug (year) | Chemical class (activity type) | Inhibition target (associated action) | MIC (mg/L) | Genetic factor | Associated function | Drug resistance | Reference |
|---|---|---|---|---|---|---|---|
| Moxifloxacin (1996) Gatifloxacin (1999) | Quinolones/8-methoxyfluroquinolone (bactericidal) | DNA gyrase and DNA topoisomerase (Inhibits DNA synthesis) | 0.5–2.5 | gyrA, gyrB | Negatively supercoils closed circular double-stranded DNA | Alteration of drug target due to mutation | [ |
| Kanamycin* (1957) Amikacin* (1972) | Amino-glycosides (bactericidal) | Inhibition of RNA-dependent synthesis by binding to 30S subunit (inhibition of protein synthesis) | 2–8 | rrs | Synthesis of stable RNAs | Mutations on 16S rRNA and overexpression machines | [ |
| eis | Acetylation, intracellular survival | ||||||
| whiB7 | Associated with transcription | ||||||
| tlyA | Methylates 16S and 23S rRNA | ||||||
| Capreomycin* (1963) | Cyclic polypeptide (bactericidal) | Inhibition of 50S subunit (inhibition of protein synthesis) | 2–4 | rrs | Synthesis of stable RNAs | Mutation alteration drug target | [ |
| tlyA | Methylates 16S and 23S rRNA | ||||||
| eis | Acetylation, intracellular survival | ||||||
| Ethionamide (1956) | Isoconitic acid derivative (bacteriostatic) | Inhibition of mycolic acid synthesis by binding to the ACP reductase InhA (disrupts cell wall biosynthesis) | 2.5–25 | ethA | Activates the pro-drug ethionamide | alteration and over-expression drug target due mutation | [ |
| ethR | Regulates transcriptional repressor protein EthR | ||||||
| KasA | Involved in fatty acid biosynthesis | ||||||
| inhA | Mycolic acid biosynthesis | ||||||
| inhA pro. | Regulation of expression of inhA | ||||||
| Dihydropteroate synthase (inhibits folate and thymine nucleotide metabolism biosynthesis) | 1–8 | thyA | Deoxyribo-nucleotide biosynthesis | Removal of pro-drug conversion procedure | [ | ||
| folC | Regulate folates to polyglutamate conversion | ||||||
| dfrA | De novo glycine and purine synthesis | ||||||
| ribD | Involved in riboflavin biosynthesis | ||||||
| Cycloserine (1955) | Serine derivative (bacteriostatic) | Inhibition of peptide-glycan synthesis by blocking d-alanine racemase enzyme (inhibition of cell wall synthesis) | 25–30 | alr | Associated with d-alanine required for cell wall biosynthesis | Overexpression of | [ |
| ddl | Involved in cell wall formation | ||||||
| Ald | Associated with cell wall synthesis | ||||||
| cycA | Transport across the cytoplasmic membrane |
*, injectable.
Genetic factors involved in third-line anti-TB drug resistance in Mycobacterium tuberculosis.
| Drug (year) | Chemical class (activity type) | Inhibition target (associated action) | MIC (mg/mL) | Genetic factor | Associated function | Drug resistance | Reference |
|---|---|---|---|---|---|---|---|
| Clofazimine (1954) | Iminophenazine derivative ( | Produces reactive oxygen, inhibits energy production, potassium transporter (inhibition of mycobacterial growth targeting mycobacterial DNA) | 0.1–1.2 | rv0678 | Transcription repressor for efflux pump MmpL5 | Upregulation of MmpL5, efflux pump due to mutation | [ |
| rv1979c | Role in the transportation of amino acid | ||||||
| rv2535c | Associated/encodes a putative peptidase PepQ. | ||||||
| ndh | Associated with oxidation and reduction reaction | ||||||
| pepQ | Possibly hydrolyse peptides | ||||||
| Bedaquiline (2012) | Quinoline (bactericidal/ bacteriostatic) | Inhibits the adenosine 5'-triphosphate synthase (inhibition of ATP synthase) | 0.06–1 | rv0678 | Transcription of efflux pump MmpL5 | Mutations on binding site and co-infection | [ |
| atpE | Encodes the c part of the F0 subunit of the ATP synthase | ||||||
| pepQ | Possibly hydrolyses peptides | ||||||
| Delamanid (2014) Pretomanid (2020) | Nitroimidazole (bactericidal) | Obstructs the synthesis of mycolic acid | 0.006–0.24/0.015–0.25 | fgd1 | Catalyzes oxidation of glucose-6-phosphate to 6-phosphogluconolactone | Mutations on reductive activating gene | [ |
| fbiC | Participates in a portion of the F420 biosynthetic pathway | ||||||
| fbiA | Required for coenzyme F420 production from FO | ||||||
| fbiB | Required for coenzyme F420 production from FO | ||||||
| ddn | Converts bicyclic nitroimidazole drug candidate pa-824–3 metabolites | ||||||
| Linezolid (2000) | Oxazolidinone ( | 50S, 23S ribosomal subunit (inhibition of protein synthesis) | 0.25–0.5 | rplC | Formation of ribosomal peptidyl-transferase | Mutation in 50S ribosomal L3 protein | [ |
| rrl | Formation of stable RNAs |